Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
Part of paid clinical trials in Irvine, California.
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Study ID
- NCT07029581
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Lewy Body Dementia Psychosis
Eligibility Criteria
- Sex
- ALL
- Age
- 55 Years - 84 Years
- Healthy Volunteers
- Not accepted
Interventions
- ACP-204 — DRUGProvided as 1 capsule, to be taken orally once daily
- Placebo — DRUGProvided as 1 capsule, to be taken orally once daily
Study Details
Multicenter, randomized, 6-week, double-blind, placebo-controlled, parallel-group, Phase 2 study in subjects with LBDP.
Key Dates
- Start date
- Aug 6, 2025
- Status verified
- Sep 2025
- Primary completion
- Feb 29, 2028
- Completion
- Mar 31, 2028
Study Design
- Enrollment
- 180 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: ACP-204 30 mgACP-204 dose of 30 mg once daily
- Experimental: ACP-204 60 mgACP-204 dose of 60 mg once daily
- Placebo Comparator: PlaceboPlacebo once daily
Primary Outcome Measure
Change from Baseline in SAPS-LBDP total score at Week 6 [ Time Frame: 6 weeks ]
Central Contacts
- Kristin Kidd434-841-3162
- Becky Howell848-702-1886
Locations (26)
Find similar trials in Irvine, CA
By research site
ATP Clinical Research Inc.· Irvine, CAGeorgetown University· Washington D.C., DCHumanity Clinical Research, Corp· Aventura, FLParkinson's Disease and Movement Disorders Center of Boca Raton· Boca Raton, FLK2 Medical Research Winter Garden LLC· Clermont, FLUniversity of Florida - Shands· Gainesville, FL
Related Studies
- Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia PsychosisPHASE3 · Enrolling By Invitation · ACADIA Pharmaceuticals Inc. · Irvine, California